Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Teropavimab and Zinlirvimab in HIV During Treatment Interruption
NCT05079451Phase 1Withdrawn
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2024
- Primary completion
- Jan 2024
- Modality
- Anti-infectious Disease mAbs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Teropavimab and zinlirvimab in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Occurrence of Grade >=3 systemic Adverse Event related to study drugs at 72 weeks and Viral rebound defined as confirmed HIV-1 RNA >200 copies/mL at 24 weeks. Planned start Jan 2024; status: withdrawn.
02
Drugs
Teropavimabzinlirvimab
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05079451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05079451.